Aurora Cannabis vs Intercure
ACB and INCR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACB and INCR compare
Intercure grew revenue faster over the last twelve months (13.1% versus 11.0% for Aurora Cannabis).
Aurora Cannabis scores higher on the StockData Score (6 against 3 for Intercure), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACB | INCR |
|---|---|---|
| Size and price | ||
| Share price | $4.61 | $3.79 |
| Change, 1 year | 5.0% | −44.3% |
| Change, 5 years | −93.2% | −90.4% |
| Beta (5Y) | 0.70 | – |
| StockData Score | ||
| Total score | 6 (better) | 3 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 0 | 2 (better) |
| Health score | 5 (better) | 0 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 11.0% | 13.1% (better) |
| Revenue growth, 5Y average | 5.5% | 33.0% (better) |
| EPS growth (TTM) | −5450% | – |
| Profitability | ||
| Gross margin | 42.6% (better) | 12.3% |
| Operating margin | – | −10.1% |
| Net margin | – | −13.2% |
| FCF margin | – | 4.9% |
| Return on equity | – | −9.0% |
| Return on invested capital | – | −4.0% |
| Financial health | ||
| Debt / equity | 0.00 | 0.49 (better) |
| Current ratio | 5.94 | – |
| Piotroski F-score | – | 5 |
| Ownership | ||
| Held by institutions | 8.9% | 0.22% |
| Held by insiders | 0.00% | 30.8% |
Go deeper
- ACB stock overview
- ACB income statement
- ACB valuation and score
- INCR stock overview
- INCR income statement
- INCR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.